| Literature DB >> 20157558 |
Irina A Vinogradova1, Vladimir N Anisimov, Andrey V Bukalev, Anna V Semenchenko, Mark A Zabezhinski.
Abstract
We evaluated the effect of various light/dark regimens on the survival, life span and tumorigenesis in rats. Two hundred eight male and 203 females LIO rats were subdivided into 4 groups and kept at various light/dark regimens: standard 12:12 light/dark (LD); natural lighting of the North-West of Russia (NL); constant light (LL), and constant darkness (DD) since the age of 25 days until natural death. We found that exposure to NL and LL regimens accelerated development of metabolic syndrome and spontaneous tumorigenesis, shortened life span both in male and females rats as compared to the standard LD regimen. We conclude that circadian disruption induced by light-at-night accelerates aging and promotes tumorigenesis in rats. This observation supports the conclusion of the International Agency Research on Cancer that shift-work that involves circadian disruption is probably carcinogenic to humans.Entities:
Keywords: life span; light-at-night; rats; tumorigenesis
Mesh:
Substances:
Year: 2009 PMID: 20157558 PMCID: PMC2816394 DOI: 10.18632/aging.100092
Source DB: PubMed Journal: Aging (Albany NY) ISSN: 1945-4589 Impact factor: 5.682
Figure 1.Dynamics of the coefficient of homeostatic stability (CHS) in female (A) and male (B) rats maintained at various light regimens. ^ The difference with the relevant parameter in the group LD is significant, р<0,05; * The difference with the parameter at the age of 3 months in the same group is significant, р<0,05 (Wilcoxon-Mann-Whytney test).
Figure 2.Age-related dynamics of incidence of irregular estrous cycles in rats maintained at various light/dark regimens. Ordinate, number of rats with irregular estrous cycles (%). The difference with the relevant parameter in the group LD is significant, р<0.05.
Effect of light regimen on survival and life span in male rats. Effect of light/dark regimen on spontaneous tumorigenesis in rats.
Notes: Difference with controls is significant: a, р<0.05. #, in brackets 95% confidential intervals. MRDT, mortality rate doubling time.
| Parameters | Light/dark regimen | |||
| LD | NL | LL | DD | |
| Number of rats | 57 | 50 | 50 | 51 |
| Mean life span, days | 644 ± 34.0 | 613 ± 32.9 | 580 ± 35.5 | 652 ± 32.5 |
| Maximum life span, days, | 1045 | 1046 | 1005 | 1017 |
| Mean life span of last 10% survivals, Days | 999 ± 11.5 | 972 ± 22.7 | 983 ± 13.8 | 987 ± 13.0 |
| α x 103, days-1 | 6.06 (5.87; 6.47) | 6.70a (6.50; 6.97) | 5.19a (4.89; 5.57) | 8.31a (8.10; 8.54) |
| MRDT, days | 112.4 (107.1; 118.1)# | 103.4 (102.7; 111.6) | 133.6a (124.4; 141.7) | 83.4a (81.2; 85.5) |
Figure 3.Effect of the exposure to various light regimens on survival and tumorigenesis in rats.
(A) - survival, males; (B)- survival- females; (C) - total tumor incidence, males; (D) - total tumor incidence, females; (E) - malignant tumor incidence, males; (F) - malignant tumorincidence, females.
Effect of light regimen on survival and life span in female rats.
Notes: Difference with controls is significant: a, р<0.05; b, р<0.01; c, р<0.001. #, in brackets 95% confidential intervals. MRDT, mortality rate doubling time.
| Parameters | Light/dark regimen | |||
| LD | NL | LL | DD | |
| Number of rats | 40 | 48 | 54 | 61 |
| Mean life span, days | 706 ± 46.2 | 611 ± 29.5 | 526 ± 30.4b | 639 ± 30.1 |
| Maximum life span, days, | 1167 | 897 | 956 | 1266 |
| Mean life span of last 10% survials, days | 1119 ± 16.7 | 830 ± 18.9 | 909 ± 19.1c | 1023 ± 56.0 |
| α x 103, days-1 | 5.00 (4.73; 5.30)# | 10.5 (10.3; 11.2)a | 5.21 (5.13; 5.35) | 4.88 (4.86; 4.97) |
| MRDT, days | 138.6 (130.8; 146.6) | 65.8 (61.7; 67.0)a | 133.1 (129.6; 135.1) | 142.0 (139.4; 142.5) |
Effect of light regimen on tumorigenesis in male rats.
Notes: TBR - tumor-bearing rats.
| Number of rats | 57 | 50 | 50 | 51 | ||
| Number of TBR (%) | 17 ( 29.8 %) | 11 (22%) | 13 (26%) | 11 (21.6%) | ||
| No. of tumors per TBR | 1.35 | 1.18 | 1.08 | 1.36 | ||
| Number of malignant TBR (%) | 7 (12.3%) | 6 (12%) | 10 (20%) | 5 (9.8%) | ||
| Total number of tumors | 23 | 13 | 14 | 15 | ||
| Time of the 1st tumor detection, days | 379 | 367 | 223 | 659 | ||
| Mean life span of TBR, days | 824 ± 49.0 | 782 ± 57.6 | 688 ± 73.2 | 805 ± 32,3 | ||
| Mean life span of malignant TBR, days | 794 ± 72.4 | 738 ± 95.6 | 701 ± 76.0 | 766 ± 49.5 | ||
| Testes: Leydigoma hemangioma | 7 | 6 | 4 | 6 | ||
| 1 | - | - | - | |||
| Malignant lymphoma/ leukemia | 3 | 4 | 6 | 3 | ||
| Liver: hepatocarcinoma | 2 | - | 2 | - | ||
| Skin: papilloma | 1 | - | - | - | ||
| Soft tisusues: fibroma sarcoma malignant fibrous histiocytoma | - | - | - | 1 | ||
| 1 | 2 | - | 1 | |||
| 2 | - | - | - | |||
| Lung: adenocarcinoma light-cell carcinoma | - | - | 1 | - | ||
| 1 | - | - | - | |||
| Small bowel: adenocarcinoma | - | - | 1 | - | ||
| Adrenal gland: cortical adenoma pheochromocytoma malignant pheochromocytoma | 3 | 1 | - | 3 | ||
| 1 | - | - | - | |||
| - | - | - | 1 | |||
| Urether: fibroma | 1 | - | - | |||
| Total: benign malignant | 14 | 7 | 4 | 10 | ||
| 9 | 6 | 10 | 5 | |||
Effect of light regimen on tumorigenesis in female rats.
Notes: TBR - tumor-bearing rats. Difference with the group LD is significant: a, р<0.05; b, р<0.01; c, р<0.001.
| Number of rats | 40 | 48 | 54 | 61 | |
| Number of TBR (%) | 21 (52.5%) | 34 (70.8%)a | 24 (44.4%) | 15 (24.6%)c | |
| No. of tumors per TBR rat | 1.38 | 1.41 | 1.63 | 1.07 | |
| No. of mlgn. TBR rats (%) | 5 (12.5%) | 7 (14.6%) | 7 (13.0%) | 3 (4.9%) | |
| Number of tumors | 29 | 48 | 39 | 16 | |
| Time of the 1st tumor detection, days | 207 | 365 | 186 | 186 | |
| Mean life span of TBR, days | 769 ± 63.0 | 683 ± 22.9b | 665 ± 40.3 | 720 ± 64.3 | |
| Mean life span of malignant TBR, days | 1098 ± 21.8 | 688 ± 56.8c | 647 ± 79.8c | 809 ± 130.5a | |
| Mammary gland: fibroma fibroadenoma adenocarcinoma | 4 | 9 | 1 | - | |
| 11 | 21 | 20 | 5 | ||
| - | - | 1 | - | ||
| No. of rats with benign mammary tumors | 14 | 27a | 18 | 5c | |
| Utery: polyp fibroma fibromyoma adenocarcinoma stromogenic sarcoma | 4 | 1 | 4 | 5 | |
| 1 | - | 1 | - | ||
| - | 2 | 1 | - | ||
| - | 3 | 1 | - | ||
| - | - | - | 1 | ||
| Oviduct: fibroma | - | 3 | - | - | |
| Adrenal gland: cortical adenoma carcinoma pheochromocytoma | 1 | 1 | 3 | 1 | |
| - | - | - | 1 | ||
| 2 | - | - | - | ||
| Ovary: fibroma luteoma hemangioma carcinoma | 1 | - | - | - | |
| - | 1 | - | - | ||
| - | - | - | 1 | ||
| - | 1 | - | - | ||
| Pituitary: adenoma | - | - | 1 | - | |
| Hematopoeitic tissue: leukemia/lymphoma | 3 | 3 | 4 | - | |
| Soft tissues: fibroma sarcoma | - | 1 | 1 | 1 | |
| 2 | 2 | 1 | - | ||
| Lung: adenocarcinoma | - | - | - | 1 | |
| Colon: adenocarcinoma | - | 1 | - | - | |
| Total: benign malignant | 24 | 39 | 32 | 13 | |
| 5 | 9 | 7 | 3 | ||
Summary evaluation of effects of various light/dark regimen on biomarker of aging and homeostatic parameters in female and male rats [ 28-35].
Notes: ↑ - increases (acceleration); ↓ - decreases (slow down); = - no effect, as compared with the parameter in the LD group; M - male; F - female.
| Parmeters | Sex | Ligh/dark regimen | |||||
| NL | LL | DD | |||||
| Body weight | Male | ↑ | = | = | |||
| Female | ↓ | ↓ | ↓ | ||||
| Body weight gain | M & F | ↓ | ↓ | ↑ | |||
| Progressive growth period | Male | ↑ | ↓ | ↑ | |||
| Stable growth period | Male | ↓ | ↓ | ↓ | |||
| Presenile period | Male | ↑ | ↑ | ↑ | |||
| Senile period onset | Male | ↑ | ↑ | ↓ | |||
| Food consumption | M & F | ↑ | ↑ | ↓ | |||
| Water consumption | Male | = | = | = | |||
| Maturity onset | M & F | ↑ | ↑ | ↓ | |||
| Estrous function switching-off | Female | ↑ | ↑ | ↓ | |||
| Diuresis | Male | ↓ | ↓ | ↓ | |||
| Morbidity | M & F | ↑ | ↑ | ↓ | |||
| Glucose (age at appearance) | Male | ↑ | ↑ | ↓ | |||
| Ketones (age at appearance) | Male | ↑ | ↑ | ↑ | |||
| Locomotor activity | Male | ↑ | ↑ | ↓ | |||
| Psychoemotional feautures | Male | ↑ | ↑ | ↓ | |||
| Cognitive function | Male | ↓ | ↓ | = | |||
| Dynamic endurance | Male | ↓ | ↓ | ↑ | |||
| Static endurance | Male | ↓ | ↓ | ↓ | |||
| Glucose | M & F | ↑ | ↑ | = | |||
| Cholesterol | M & F | ↑ | ↑ | = | |||
| Β-lipoproteins | M & F | ↑ | ↑ | = | |||
| Total protein | M & F | ↓ | ↓ | ↑ | |||
| Urea | M & F | ↑ | ↑ | = | |||
| Creatinine | M & F | ↑ | ↑ | = | |||
| Sodium | M & F | = | = | = | |||
| Potassium | M & F | = | ↓ | ↑ | |||
| Prolactin | M & F | ↑ | ↑ | ↓ | |||
| C-peptide | M & F | ↑ | ↑ | = | |||
| TSH | M & F | ↓ | ↓ | = | |||
| Т4 | M & F | ↑ | ↑ | = | |||
| T3 | M & F | ↓ | = | ↑ | |||
| Coefficient of homeo-static stability (CHS) | M & F | ↓ | ↓ | ↑ | |||
| Liver | M & F | ↓ | = | = | |||
| Kidney | M & F | = | ↓ | = | |||
| Heart | M & F | ↓ | ↓ | = | |||
| Skeletal muscles | M & F | ↓ | ↓ | = | |||
| Life span | Male | = | = | = | |||
| Female | ↓ | ↓ | ↑ | ||||
| Spontaneous carcinogenesis | M & F | ↑ | ↑ | ↓ | |||